Proteolix Initiates Phase 1b Clinical Trial Of Carfilzomib In A Combination Regimen For Patients With Relapsed Multiple Myeloma

Proteolix, Inc. announced that patient dosing has commenced in a Phase 1b clinical trial to evaluate the safety and efficacy of Proteolix’s lead anti-cancer agent, carfilzomib (PR-171), in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma. Carfilzomib selectively blocks proteasome activity, causing apoptosis in cancer cells.

More: continued here

Filed under: Blood on July 16th, 2008